Abstract. HS1 associated protein X-1 (HAX-1), a substrate of Src family tyrosine kinases, plays a critical role in cell apoptosis. However, its functions in prostate cancer remains unclear. The present study explored the role and mechanism of HAX-1 in cancer cell apoptosis. The mRNA and protein levels of HAX-1 in the prostate cancer cell lines PC-3, VCaP and DU145 were assessed. Cell proliferation, apoptosis and caspase-9 activities were assessed in DU145 after HAX-1 siRNA treatment. The mRNA and protein levels of HAX-1 in prostate cancer cell lines PC-3, VCaP and DU145 were significantly higher than those in the primary prostate epithelial cells, and DU145 possess the highest mRNA and protein levels compared to PC-3 and VCaP. When HAX-1 was knocked down in DU145, cell proliferation was significantly decreased, accompanied by a decrease in Ki67 protein expression. Compared with the control and control siRNA groups, HAX-1 siRNA promoted cell apoptosis and caspase-9 activation in DU145. Furthermore, prostate cancer cells co-transfected with HAX-1 and caspase-9 promoted viability and reduced apoptosis. In contract, co-transfection of caspase-9 and HAX-1 siRNA suppressed the cell viability and enhanced apoptosis. In summary, the present study demonstrated that HAX-1 inhibits cell apoptosis through caspase-9 inactivation.
Introduction
Prostate cancer is one of the leading cause of cancer-related death in males, second only to lung cancer (1) . Multiple genetic and epigenetic factors have been implicated in the oncogenesis and progression of prostate cancer. Prostate cancer initially responds well to androgen deprivation, but this treatment results in the emergence of androgen-independent disease that is resistant to apoptosis (2) .
HS1-associated protein X-1 (HAX-1) originally identified as a 35 kDa protein that interacts with HS1, is a substrate of Src family tyrosine kinases (3) . The HAX-1 gene is ubiquitously expressed among tissues (4) , and its protein is localized mainly in mitochondria, and also in endoplasmic reticulum and nuclear envelope in the cells.
HAX-1 was suggested to be involved in the regulation of apoptosis (programmed cell death) (3) . As an anti-apoptosis factor, the anti-apoptotic, cell-protecting properties of HAX-1 as well as its interactions with apoptosis-related proteins have been widely reported (5, 6) . HAX-1 has been reported to protect the cultured cells against the challenge of H 2 O 2 (7) . HAX-1 is highly expressed in colorectal cancer and contributes to the malignant progression and predict poor prognosis for patients with colorectal cancer (8) . So far, the expression levels and the effect of HAX-1 in prostate cancer remain unclear.
Caspase-9, a protein also localized mainly in mitochondria is a key regulatory player in the mitochondria-mediated apoptosis pathway. Activated caspase-9 directly cleaves and activates caspase-3 and -7, resulting in the biochemical destruction of the cells (9) . The inhibitor of apoptosis proteins (IAPs) have been thought to be the only class of proteins that directly inhibits caspase-9 as previously described (10), however, new mechanistic evidence showed that HAX-1 averts cell death by blocking the biological activation of caspase-9.
In the present study, we investigated the expression of HAX-1 in prostate cancer cell lines, PC3, VCaP and DU145. The role and the underlying mechanism of HAX-1 and caspase-9 interaction in prostate cancer cell apoptosis were also explored.
Materials and methods
Cell lines and cell culture. The primary human prostate epithelial cells and the human prostate cancer cell lines PC3, VCaP and DU145 were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). The primary human prostate epithelial cells were cultured in Dulbecco's modified Eagle's medium (DMEM), and the human prostate cancer cell lines PC3, VCaP and DU145 were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS), 2 mmol/l HAX-1 inhibits apoptosis in prostate cancer through the suppression of caspase-9 activation
GlutaMAX and 1% antibiotics (Invitrogen, Carlsbad, CA, USA) at 37˚C in a humidified 5% CO 2 incubator. These cells were maintained in the appropriate medium and passaged every three days.
siRNA transfection. HAX-1 and control siRNAs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). For transfection, 5x10 4 cells were seeded in each well of 24-well microplates and grown for 24 h to reach 60-65% confluency, and then incubated with a mixture of siRNA and Lipofectamine 2000 reagent (Invitrogen) in 100 µl of serum-free Opti-MEM according to the manufacturer's instructions. The transfection efficiency was examined by real-time PCR and western blotting.
Construction of expression vectors and cell transfection.
Total RNA from cells were isolated using TRIzol reagent (Invitrogen), and then converted to cDNA using the PrimeScript ® RT reagent kit (Takara, Dalian, China) with oligo(dT) primers.
Then, the open reading frame of caspase-9 cDNA was cloned and inserted into the pcDNA3.1 vector (Invitrogen) to construct the recombinant pcDNA3.1-caspase-9 expression vector. Control and pcDNA3.1 vector transfected cells were also prepared. For cell transfection, cells were cultured to 60% confluency and transfection was performed using the FuGENE HD transfection reagent (Roche, Indianapolis, IN, USA) method as suggested by the manufacturer.
Real-time PCR (RT-PCR).
Total RNA was isolated as previously described. Primers for HAX-1 were designed as: 5'-AAC CAGAGAGGACAATGATCT-3' (sense), and 5'-AAGTTGTCC AAAGAAACCTGT-3' (antisense). β-actin was used as the normalization control for HAX-1 and caspase-9 gene. The 25 µl reaction mixture contained 12.5 µl 2X OneStep qRT-PCR buffer, 0.5 µM reverse and 0.5 µM forward primer, 0.9 µl enzymix, 90 ng RNA template and 0.5 µM probe. PCR conditions for the reverse transcription used to obtain cDNA were as follows: 45˚C for 10 min, pre-denaturation at 95˚C for 10 min and then 45 cycles of 95˚C for 15 sec and 60˚C for 45 sec; this was performed using the ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Real-time RT-PCR was performed in a Rotor-Gene RG-3000 Real-Time Thermal Cycler (Corbett Research, Sydney, Australia).
Western blotting. The proteins were extracted from cells using RIPA lysis buffer (Beyotime, Nantong, China). For western blotting, equal amounts of proteins were separated on SDS-PAGE and blotted onto a pre-wet nitrocellulose membrane (GE Healthcare, Germany), followed by blocking of membranes in 10% defatted milk in phosphate-buffered saline (PBS) at 4˚C overnight, the membranes were then probed with different primary antibodies. The primary antibodies were as follows: mouse anti-HAX-1, mouse antiBcl-2, mouse anti-Bax and mouse anti-β-actin antibodies (Santa Cruz Biotechnology), rabbit anti-caspase-9 antibody (Abcam, Cambridge, UK). After washing with TBST buffer, the membranes were incubated for 1 h at 25˚C with HRP-conjugated secondary antibodies. ECL reagent was used for detection. The fluorescence was scanned using a Typhoon scanner (Amersham Biosciences, Piscataway, NJ, USA). All experiments were performed in triplicate.
Cell viability. The cell viability measurements were carried out using the MTT assay. Approximately 5x10 4 cells were seeded into 96-well plates, washed twice with PBS and 10 µl of MTT was added to each well. Then, the cells were incubated at 37˚C for 2 h and 100 µl dimethylsulfoxide (DMSO) was added to dissolve the formazan crystals. Absorbance was measured at 560 nm with a SpectraMax Paradigm Multi-Mode Reader (Molecular Devices, Austria).
Cell apoptosis.
Flow cytometry was used to analyze cell apoptosis and Annexin V-propidium iodide (AV-PI) staining was performed. Briefly, after treatment cells were harvested and washed three times with PBS. Following centrifugation for 10 min, cells were resuspended in 500 µl of binding buffer including 5 µl FITC-conjugated Annexin V, the mixture was incubated in the dark for 10 min, and then 5 µl of PI was added. Ultimately, all specimens were assessed by flow cytometry with a FACSCalibur using CellQuest software (BD Biosciences, San Jose, CA, USA), and all the results are shown as a percentage of total cells, to quantitatively evaluate the rate of apoptosis.
Caspase-9 activity. The caspase-9 activity was assayed using the Caspase-9 Assay kit (Abcam), according to the manufacture's instruction. The fresh protein lysates from cells were prepared using cell lysis buffer. Then, 85 µl of reaction buffer and 5 µl of LEHD-pNA (Leu-Glu-His-Asp-p-nitroanilide) were added to each sample and incubated at 37˚C for 2 h. The absorbance was measured in an ELISA reader (Labsystems, Helsinki, Finland) at 405 nm.
Statistical analysis. The SPSS version 19.0 software (SPSS, Inc., Chicago, IL, USA) was used to analyze the related data with χ 2 or t-tests. The results were considered to indicate a statistically significant result at P<0.05.
Results

HAX-1 is highly expressed in human prostate cancer cell lines.
To investigate the expression of HAX-1 in human prostate cancer cells, we used RT-PCR to detect HAX-1 mRNA levels and western blotting to analyze the protein levels in normal human primary prostate epithelial cells, and the prostate cancer cell lines PC3, VCaP and DU145. RT-PCR analysis showed that the mRNA levels of HAX-1 in the prostate cancer cell lines were higher than that in the normal cells (Fig. 1A) . Consistent with the results of mRNA levels, the protein levels in different prostate cancer cells were higher than that in the normal cells (Fig. 1B) . It is noteworthy, that both the mRNA and protein levels of HAX-1 in DU145 were higher than those in PC3 and VCaP.
Expression levels of HAX-1 in HAX-1 knockdown DU145 cells. On the basis that the expression of HAX-1 is higher in the DU145 cells than the other two prostate cancer cell lines, PC3 and VCaP, we generated HAX-1 knockdown DU145 cells by HAX-1 siRNA to investigate the function of HAX-1 in prostate cancer cells. After HAX-1 siRNA treatment, the mRNA and protein levels of HAX-1 were significantly decreased (Fig. 2) . These results confirmed that the HAX-1 knockdown-DU145 cells were successfully established.
Effect of HAX-1 knockdown on cell proliferation.
Cell proliferation was assessed in DU145 cells after HAX-1 siRNA treatment by the MTT analysis. The results revealed that HAX-1 knockdown significantly decreased the cell viability compared to the other two groups (P<0.05; Fig. 3A ). No differences were detected between the control and control siRNA-treated cells. Ki67 has been used as a marker for cell proliferation in cancer. We further analyzed the Ki67 protein expression levels, and revealed that HAX-1 siRNA suppressed the Ki67 protein expression (Fig. 3B) .
Effect of HAX-1 knockdown on cell apoptosis.
We next investigated the role of HAX-1 on DU145 apoptosis, after HAX-1 siRNA treatment. As shown in Fig. 4 , TRAF4 knockdown notably increased cell apoptosis from 13 to 56% when compared to the control groups. No difference was found between the control and control siRNA groups (P<0.05; Fig. 4A and B) . Moreover, HAX-1 siRNA also induced the pro-apoptosis protein Bax, whereas inhibited the anti-apoptosis protein Bcl-2 expression (Fig. 4C) . These data reflected that HAX-1 is an anti-apoptosis factor in prostate cancer.
HAX-1 knockdown enhances viability and inhibits apoptosis in prostate cancer cells by caspase-9 inhibition.
Caspase-9 is a critical regulator of mitochondria-mediated apoptosis, and HAX-1 is one of the molecules that interacts with caspase-9 (11). To determine whether HAX-1 interacts with caspase-9 in the progress of prostate cancer viability and apoptosis, the activity of caspase-9 was determined in DU145 cells after HAX-1 knockdown. The results showed that HAX-1 knockdown markedly increased caspase-9 activity (P<0.05; Fig. 5A ). The results of western blotting showed that HAX-1 knockdown promoted caspase-9 processing in DU145 cells. These results indicated that HAX-1 is a negative regulator of caspase-9 activation. 
HAX-1 enhances prostate cancer cell viability and apoptosis through inhibit caspase-9 activation.
To further explore the function of caspase-9 signaling in HAX-1-induced prostate cancer viability and apoptosis, caspase-9, HAX-1 and HAX-1 siRNA were co-transfected to DU145 cells. As shown in Fig. 6A , cell viability was significantly increased in caspase-9 and HAX-1 co-transfected cells compared to caspase-9 only transfected cells. Moreover, the cell viability in caspase-9 and HAX-1 siRNA co-transfected cells was sharply decreased when compared to caspase-9 and control siRNA co-transfected cells (P<0.05). The cell apoptosis in caspase-9 and HAX-1 co-transfected cells was markedly decreased when compared to the caspase-9 only transfected cells. Furthermore, cell apoptosis in caspase-9 and HAX-1 siRNA co-transfected cells was notably increased when compared to the caspase-9 and control siRNA co-transfected cells (P<0.05).
Discussion
Induction of differentiation and apoptosis in cancer cells is a critical approach in cancer therapy (12) . Substantial research has focused on the induction of apoptosis in prostate cancer. For example, Hsieh and Wu showed that resveratrol treatment is able to induce apoptosis in prostate cancer (13) , and Hsu et al showed that the cyclooxygenase-2 inhibitor celecoxib induces apoptosis in human prostate cancer cells by blocking Akt activation (14) . In fact, the regulation of apoptosis relies on multiple cell signaling mechanisms, cancer cells can employ a number of different strategies to suppress a protective apoptotic response, contributing to cancer development by promoting cell survival and resistance to antineoplastic drugs (15) (16) (17) . In this regard, new anticancer therapeutics are needed to focus on the induction of cancer cell apoptosis through activation of the apoptotic pathway (18) .
HAX-1 is a family of apoptotic regulators in disease including cancer (19) (20) (21) . It has been reported that HAX-1 is highly expressed in different human melanoma cell lines (22) . In this research, we first investigated that HAX-1 is highly expressed in prostate cancer cells, and further analysis found that HAX-1 knockdown sharply decreased prostate cancer cell proliferation and the expression of cell proliferating marker, Ki67. Moreover, HAX-1 knockdown significantly promoted apoptosis, enhanced the pro-apoptosis protein Bax, and inhibited the anti-apoptosis protein Bcl-2 expression in prostate cancer. These data indicate that HAX-1 is an anti-apoptosis molecule in prostate cancer. Cell apoptosis is a complex process regulated by several molecules that function as either promoters, including Bax, Bak and caspases, or inhibitors of the cell death process such as Bcl-2, Bcl-xL and the IAPs (23) (24) (25) (26) (27) . In addition, HAX-1 has been shown to interact with a number of cellular and viral proteins, thus confirming its involvement in multiple signaling pathways and cellular processes (28, 29) .
In recent years, many cellular factors involved in apoptosis have been identified and their roles in the apoptotic pathway has been elucidated (30) . Mitochondria is a key participant in cell death, and apoptotic cell death is characterized by a host of morphological and biochemical features, mitochondrial outer membrane permeabilization (MOMP) and the release of pro-apoptotic proteins (31) . Activation of the BCL-2 family members Bax and Bak results in MOMP, and release of the pro-apoptotic proteins, such as cytochrome c from the inter-membrane space into the cytosol. Cytochrome c binds Apaf-1 forming the apoptosome and activating caspase-9. Once active, caspase-9 directly cleaves and activates caspase-3 and caspase-7 (32) (33) (34) . It has been found that HAX-1 directly binds to caspase-9, leading to post-mitochondrial inactivation of caspase-9, thus blocking the caspase-9-mediated cell apoptosis pathway in cardiac myocytes (9) . It is noteworthy that we found, that HAX-1 knockdown enhanced caspase-9 activity, further experiments demonstrated that prostate cancer cell co-transfected with HAX-1 and caspase-9 promoted cell viability and reduced cell apoptosis. In contract, co-transfection of caspase-9 and HAX-1 siRNA suppressed cell viability and enhanced apoptosis. This phenomenon, provides evidence that the HAX-1, inhibits cell apoptosis through caspase-9 inactivation.
In summary, in the present study we propose a new mechanism to account for apoptosis in prostate cancer by HAX-1 inhibition. A better understanding of this process could lead to the development of novel therapeutic strategies aimed at reducing tumor growth and the development of prostate cancer.
